Go Pro
→ Central banks bought 710 tonnes - this fund pays monthly (From Investors Alley) (Ad)tc pixel Free RVX Stock Alerts

Resverlogix (RVX) Competitors

Resverlogix logo
C$0.10 +0.01 (+5.00%)
As of 01:45 PM Eastern
Compare

RVX vs. HBP, SCYB, COM, NVH, and PDP

Should you buy Resverlogix stock or one of its competitors? Resverlogix's main competitors and comparable companies include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Pediapharm (PDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Resverlogix compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Helix BioPharma had 1 more articles in the media than Resverlogix. MarketBeat recorded 2 mentions for Helix BioPharma and 1 mentions for Resverlogix. Helix BioPharma's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helix BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Resverlogix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Resverlogix's return on equity of 6.67% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Resverlogix N/A 6.67%-34.90%

Helix BioPharma has a beta of 0.433836, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Resverlogix has a beta of 0.348419, suggesting that its stock price is 65% less volatile than the broader market.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.0% of Resverlogix shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Comparatively, 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Helix BioPharma is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
ResverlogixN/AN/A-C$2.81M-C$0.02N/A

Summary

Resverlogix beats Helix BioPharma on 7 of the 9 factors compared between the two stocks.

How does Resverlogix compare to Scythian Biosciences?

Resverlogix (TSE:RVX) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Resverlogix's return on equity of 6.67% beat Scythian Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 6.67% -34.90%
Scythian Biosciences N/A N/A N/A

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.02N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

In the previous week, Resverlogix had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Scythian Biosciences. Resverlogix's average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
Scythian Biosciences Neutral

Summary

Resverlogix beats Scythian Biosciences on 4 of the 5 factors compared between the two stocks.

How does Resverlogix compare to 138267 (COM.TO)?

Resverlogix (TSE:RVX) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Resverlogix had 1 more articles in the media than 138267 (COM.TO). MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for 138267 (COM.TO). Resverlogix's average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
138267 (COM.TO) Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.02N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

Resverlogix's return on equity of 6.67% beat 138267 (COM.TO)'s return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 6.67% -34.90%
138267 (COM.TO) N/A N/A N/A

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Resverlogix beats 138267 (COM.TO) on 4 of the 5 factors compared between the two stocks.

How does Resverlogix compare to Novoheart?

Resverlogix (TSE:RVX) and Novoheart (CVE:NVH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Resverlogix had 1 more articles in the media than Novoheart. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Novoheart. Resverlogix's average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
Novoheart Neutral

Resverlogix's return on equity of 6.67% beat Novoheart's return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 6.67% -34.90%
Novoheart N/A N/A N/A

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Resverlogix has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.02N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

Summary

Resverlogix beats Novoheart on 7 of the 9 factors compared between the two stocks.

How does Resverlogix compare to Pediapharm?

Pediapharm (CVE:PDP) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Resverlogix has lower revenue, but higher earnings than Pediapharm. Resverlogix is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16M5.95-C$16.15M-C$0.07N/A
ResverlogixN/AN/A-C$2.81M-C$0.02N/A

Resverlogix's return on equity of 6.67% beat Pediapharm's return on equity.

Company Net Margins Return on Equity Return on Assets
PediapharmN/A N/A N/A
Resverlogix N/A 6.67%-34.90%

In the previous week, Resverlogix had 1 more articles in the media than Pediapharm. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Pediapharm. Pediapharm's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Pediapharm Neutral
Resverlogix Neutral

Summary

Resverlogix beats Pediapharm on 6 of the 9 factors compared between the two stocks.

Get Resverlogix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVX vs. The Competition

Export
MetricResverlogixBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$33.28MC$3.74BC$7.06BC$12.54B
Dividend Yield7.02%3.69%2.57%6.20%
P/E Ratio-5.2510.67269.0630.69
Price / SalesN/A1,294.08602.439.75
Price / Cash132.50102.8870.4882.29
Price / Book-0.3516.7812.914.60
Net Income-C$2.81M-C$13.32MC$3.45BC$299.09M
7 Day PerformanceN/A1.74%1.12%0.94%
1 Month PerformanceN/A1.60%1.79%3.90%
1 Year Performance-4.55%56.43%67.69%36.05%

Resverlogix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVX
Resverlogix
N/AC$0.11
+5.0%		N/A-8.7%C$33.28MN/AN/A19
HBP
Helix BioPharma
N/AC$1.50
flat		N/A+60.7%C$114.57MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:RVX) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel